Clinical trial

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-03-01

PhasePHASE2

Study timeline

Study start (unknown)2009-03-01Date precision: month

Registry last updated2022-11-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

LY2140023DRUG

aripiprazoleDRUG · verified · RxNorm: aripiprazole

olanzapineDRUG · verified · RxNorm: olanzapine

risperidoneDRUG · verified · RxNorm: risperidone

Sponsors & collaborators

Denovo Biopharma LLClead sponsor

Mapped research locations

ChicagoIllinois, United States1 Washington D.C.District of Columbia, United States1 IndianapolisIndiana, United States1 Oklahoma CityOklahoma, United States1 MoscowRussia1 Saint PetersburgRussia1 Mexico CityMexico1 MonterreyMexico1 Garden GroveCalifornia, United States1 MannheimGermany1 GuadalajaraMexico1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00845026 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.